Fat tissue secrets: can a diabetes drug protect kidneys?
NCT ID NCT07187830
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 29 times
Summary
This study looks at how semaglutide, a diabetes and weight-loss drug, affects fat around the kidneys, heart, and liver in people with type 2 diabetes and chronic kidney disease. Researchers want to understand if changes in fat tissue can slow kidney disease. About 52 adults from University of Alberta diabetes clinics will join, with or without semaglutide treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY & OVERWEIGHT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mazankowski Alberta Heart Institute
RECRUITINGEdmonton, Alberta, T6G 2B7, Canada
Contact Email: •••••@•••••
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.